脑瘤、脑胶质瘤、神经外胚胎层肿瘤的医学论文

[061] 经过工程改造以表达GD2特异性抗原受体的NK细胞对神经外胚层起源的肿瘤细胞具有内置的ADCC样活性。

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

http://europepmc.org/article/MED/21595822

[061A] 37例听神经鞘瘤的单核细胞浸润、HLA-Dr表达及增殖。

Mononuclear cell infiltrate, HLA-Dr expression and proliferation in 37acoustic schwannomas.

http://europepmc.org/article/MED/2134396

[061B] 炎性生物标志物与特发性突发性感音神经性聋发病及预后的关系

Correlations of inflammatory biomarkers with the onset and prognosis of idiopathic sudden sensorineural hearing loss.

http://europepmc.org/article/MED/22872174

[062] 生理和药理学刺激诱导的分化导致神经母细胞瘤细胞抗原性增强。

Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells.

http://europepmc.org/article/MED/18268541

[063] 胶质瘤的免疫治疗：自然杀伤细胞治疗的局限性和潜力。

胶质瘤的免疫治疗：自然杀伤细胞治疗的局限性和潜力。

http://europepmc.org/article/MED/21507717

[064] 激活成人复发性恶性神经胶质瘤的腔内白介素2和淋巴因子的杀伤细胞后，可提高延长期生存率。

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

http://europepmc.org/article/MED/8625188

[065] 肿瘤内淋巴因子激活的杀伤细胞作为原发性胶质母细胞瘤的辅助治疗。

Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.

http://europepmc.org/article/MED/19816190

[066] 恶性胶质瘤的过继细胞免疫治疗。

Adoptive cellular immunotherapy for the treatment of malignant gliomas.

http://europepmc.org/article/MED/11418300

[067] 复发性胶质母细胞瘤切除术后自体淋巴因子激活杀伤细胞（LAK）的腔内植入。

Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.

http://europepmc.org/article/MED/15314549

[068] NK细胞转输治疗恶性复发性脑胶质细胞瘤分析

http://d.old.wanfangdata.com.cn/Periodical/gwyx-myxfc201001021